 | |
| Clinical data | |
|---|---|
| Trade names | Oragrafin |
| Routes of administration | oral,Intravenous |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.013.587 |
| Chemical and physical data | |
| Formula | C12H12I3N2NaO2 |
| Molar mass | 619.943 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 168–169 °C (334–336 °F) |
| |
| |
Ipodate sodium (sodium iopodate) is aniodine-containing radiopaquecontrast media used forX-rays. The drug is given orally and the resulting contrast allows for easy resolution of the bile duct and gall bladder.
Although not FDA approved, ipodate sodium has been used to treatGraves' disease andthyroid storm, an extreme form of hyperthyroidism.
Long-term treatment of Graves' disease with ipodate sodium (500 mg, daily) given by mouth reduced levels ofT3 andT4 in the patients.[1] This was done with minimal side effects, indicating possible clinical usefulness. Iodine uptake was also noted to return to normal within seven days, indicating control with ipodate with rapid follow up treatment with131I is feasible.
In emergency situations, ipodate can be administered forthyroid storm. As the ipodate is metabolized, it releases iodine into circulation, helping bring theT3 andT4 levels back down. Ipodate also inhibits the conversion of T4 to T3 (which is more potent). It is not considered a first-line approach, aspotassium iodide andbeta blockers have less potential for side-effects. Ipodate sodium lacks FDA approval for this use.